Scientists at The University of Texas MD Anderson Cancer Center have discovered that adding an immune-boosting therapy to standard antifungal treatment can rescue the body's defenses against life-threatening mold infections—a breakthrough that could reshape how doctors treat some of the most dangerous infections faced by cancer patients.
The study, led by Dr. Sebastian Wurster and Dr. Dimitrios P. Kontoyiannis of the Infectious Diseases, Infection Control and Employee Health department, was published in the Proceedings of the National Academy of Sciences. Their findings address a critical gap in modern medicine: despite having an expanded arsenal of antifungal drugs, doctors still struggle to save patients whose immune systems have essentially given up the fight against invasive molds in the lungs.
The key insight came from understanding how certain opportunistic molds hijack the immune system. When these fungi infect lung tissue, they trigger a condition called "immune paralysis"—T cells, the immune system's frontline soldiers, become exhausted and stop mounting a proper defense, allowing the infection to spread unchecked. The researchers found that even when antifungal medications killed fungal cells, this immune paralysis persisted, crippling recovery.
The solution was unexpected but elegant: the team used anti-PD-L1 immune checkpoint inhibitors—drugs designed and approved to help cancer patients by freeing T cells to attack tumor cells. When added early to antifungal treatment, these same drugs reenergized exhausted T cells in the context of fungal infection, allowing them to fight back effectively. In the preclinical models tested, this combination dramatically improved outcomes compared to antifungals alone.
Timing proved crucial. The researchers deliberately mimicked real clinical scenarios by starting treatment shortly after symptoms would appear in patients, testing whether beginning immunotherapy three days versus five days after fungal exposure made a difference. It did—earlier intervention produced significantly better results. This window of opportunity exists because immunocompromised patients, particularly those with cancer, initially mount some immune response, but their systems shut down rapidly. The team identified that early intervention could prevent irreversible immune collapse before it takes hold.
Dr. Kontoyiannis emphasized the urgency: "Despite an expanded arsenal of antifungal treatments, immune system dysfunction is still a major cause of failure when treating infections, with significantly high morbidity and mortality rates associated with pneumonias caused by opportunistic molds. There is an urgent need for adjunct immune-enhancing therapies to improve outcomes."
The findings reframe invasive fungal pneumonia not simply as an infection to be eradicated, but as a dual problem—one requiring both antifungal medication and immune restoration. This conceptual shift opens possibilities for treating other mold-related infections using similar combination approaches.
The work remains in preclinical models, so the path to human trials is still ahead. But the framework is clear: combining traditional antifungal drugs with immune checkpoint inhibitors given early in infection could transform outcomes for a vulnerable population. Further preclinical and clinical exploration is needed to validate this approach and potentially expand it to other life-threatening fungal pneumonias.